Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Diagnosing type 1 diabetes in adults just got clearer. The ADA and EASD released a 2026 consensus update focused on distinguishing T1D from T2D in adults, where misdiagnosis rates can reach 40%. The guidance introduces a step-by-step algorithm using islet autoantibodies and C-peptide testing, and adds new sections on cardiovascular risk, obesity, and psychosocial care.
Diagnosing type 1 diabetes (T1D) in adults has long been tricky — and a new 2026 consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) aims to fix that. The updated guidance, published in both Diabetes Care and Diabetologia, zeroes in on how to accurately differentiate T1D from type 2 diabetes (T2D) in adults with new-onset diabetes, a distinction that's far from straightforward.
The report introduces a clear diagnostic algorithm: test for islet autoantibodies (IAbs) first — two or more positives (or one strongly positive) confirms T1D. If IAbs are negative or borderline, C-peptide levels below 0.6 ng/mL support a T1D diagnosis. The guidance also discourages use of the term "LADA," calling it a confusing label with no universally accepted criteria — it's simply T1D, the authors say.
Key Takeaways:
Why it matters: T1D misdiagnosis in adults leads to delayed insulin therapy and worse outcomes. Clearer diagnostic tools and expanded management guidance could meaningfully improve care for a population that's often overlooked.